‌

US Patent 12122834 Anti-PD-1 antibodies

Patent 12122834 was granted and assigned to Merck Sharp & Dohme Limited on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Merck Sharp & Dohme Limited

0

Current Assignee

Merck Sharp & Dohme Limited

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Veronica Juan0

Shaopeng Huang0

Laurence Fayadat-Dilman0

Hua Ying0

Shireen Khan0

Date of Patent

October 22, 2024

0

Patent Application Number

169656160

Date Filed

January 31, 2019

0

Patent Citations

US Patent 10188730 Anti-LAG3 antibodies and antigen-binding fragments

0

US Patent 11136408 Anti-PD-1 antibodies, method for producing same and method for using same

0

US Patent 11072658 Anti-PD-1/LAG3 bispecific antibodies

0

US Patent 7029872 Methods for producing modified glycoproteins

0

US Patent 7449308 Combinatorial DNA library for producing modified N-glycans in lower eukaryotes

0

US Patent 8354509 Antibodies to human programmed death receptor PD-1

0

US Patent 8592562 Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects

0

US Patent 9248181 Methods and means for the production of Ig-like molecules

0

Patent Primary Examiner

0

CPC Code

0

0

0

Patent abstract

The present invention relates to anti-PD-1 antibodies and antigen-binding fragments, and use of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12122834 Anti-PD-1 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.